HER2+ Advanced Breast Cancer: Selecting Third-Line Therapy
Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.
Third-Line Treatment Data for HER2+ Advanced Breast Cancer
Sara A. Hurvitz, MD, and Steven E. Vogl, MD, highlight key concepts from a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.